Anzeige
Mehr »
Login
Montag, 15.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Im Fokus der Anleger: InnoCan Pharma vor entscheidendem Meilenstein!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14R82 | ISIN: BE0974281132 | Ticker-Symbol: 8XB
Lang & Schwarz
15.04.24
18:40 Uhr
0,290 Euro
-0,290
-100,00 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
BIOCARTIS GROUP NV Chart 1 Jahr
5-Tage-Chart
BIOCARTIS GROUP NV 5-Tage-Chart
RealtimeGeldBriefZeit
0,2590,32018:41

Aktuelle News zur BIOCARTIS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
10.01.Press release Biocartis Group NV: Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of major shareholdings)6
10.01.Press release Biocartis Group NV: Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of large shareholdings)8
22.11.23Biocartis Group NV: Biocartis Holdings Inc.: Recapitalization completed and product portfolio expansion326PRESS RELEASE - 22 November 2023, 10:00 CET BIOCARTIS HOLDINGS INC. RECAPITALIZATION COMPLETED AND PRODUCT PORTFOLIO EXPANSION The recapitalization of Biocartis was completed last week, strengthening...
► Artikel lesen
13.11.23Biocartis Group NV: Biocartis Hosts Corporate Workshop and Announces Seven Idylla Abstracts to be Presented at AMP 2023 Annual Meeting2
31.10.23Biocartis Group NV: Announcement regarding Enforcement by Secured Creditors5
20.10.23Biocartis Group NV: Four Abstracts Showing Excellent Data for Idylla Presented at European Society of Molecular Oncology Congress (ESMO)259PRESS RELEASE 20 October 2023, 07:00 CEST Four Abstracts Showing Excellent Data for Idylla Presented at European Society of Molecular Oncology Congress (ESMO) Mechelen, Belgium, 20 October 2023 -...
► Artikel lesen
26.09.23Biocartis Group NV: Biocartis announces H1 2023 Results and provides an update on the operational reorganization and recapitalization625PRESS RELEASE: INSIDE INFORMATION / REGULATED INFORMATION 26 September 2023, 07:00 CEST BIOCARTIS ANNOUNCES H1 2023 RESULTS AND PROVIDES AN UPDATE ON THE OPERATIONAL REORGANIZATION AND RECAPITALIZATION...
► Artikel lesen
26.09.23Biocartis Group NV: Agreement regarding recapitalization of operating subsidiaries by secured by secured creditors and wind down of listed holding company249PRESS RELEASE:INSIDE INFORMATION / REGULATED INFORMATION 26 September 2023, 07:00 CEST AGREEMENT REGARDING RECAPITALIZATION OF OPERATING SUBSIDIARIES BY SECURED CREDITORS AND WIND DOWN OF LISTED HOLDING...
► Artikel lesen
25.09.23XFRA 8XB: AUSSETZUNG/SUSPENSION294DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILBIOCARTIS GR. 144A/REG...
► Artikel lesen
28.08.23Biocartis Group NV: Biocartis appoints new Medical Advisory Board (MAB) of renowned practice leaders1.052PRESS RELEASE: 28 August 2023, 7:00 AM CEST Biocartis appoints new Medical Advisory Board (MAB) of renowned practice leaders Mechelen, Belgium, 28 August 2023 - Biocartis Group NV (the 'Company' or...
► Artikel lesen
10.08.23Biocartis Group NV: Biocartis Partners with Lilly to Explore Biomarker Testing for NSCLC Patients using the Idylla Platform446PRESS RELEASE: 10 August 2023, 07:00 CEST Biocartis Partners with Lilly to Explore Biomarker Testing for NSCLC Patients using the Idylla PlatformMechelen, Belgium, 2023 - Biocartis Group NV (the 'Company'...
► Artikel lesen
18.07.23Biocartis Group NV: Biocartis appoints George Cardoza as new CFO and Head of Service Delivery339PRESS RELEASE - INSIDE INFORMATION/ REGULATED INFORMATION18 July 2023, 7:00 AM CEST Biocartis appoints George Cardoza as new CFO and Head of Service Delivery George Cardoza appointed as Biocartis'...
► Artikel lesen
16.06.23XFRA 8XB: WIEDERAUFNAHME/RESUMPTION365FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME...
► Artikel lesen
16.06.23XFRA 8XB: AUSSETZUNG/SUSPENSION398DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILBIOCARTIS GR. 144A/REG...
► Artikel lesen
05.06.23Biocartis Group NV: Biocartis announces resignation CFO412PRESS RELEASE REGULATED INFORMATION - INSIDE INFORMATION 5 June 2023, 17:40 CEST BIOCARTIS ANNOUNCES RESIGNATION CFO Mechelen, Belgium, 5 June 2023 - Biocartis Group NV (the 'Company' or 'Biocartis')...
► Artikel lesen
20.04.23Biocartis Group NV: Biocartis Reports Results of First Quarter of 2023241PRESS RELEASE: REGULATED INFORMATION20 April 2023, 07:00 CEST Biocartis Reports Results of First Quarter of 2023:16% Growth of Oncology Cartridge RevenuesGross Margin on Products of 37% and EBITDA of...
► Artikel lesen
16 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1